Development of novel therapy for malignant mesothelioma by controllingADCC activity.

通过控制 ADCC 活性开发恶性间皮瘤的新疗法。

• 批准号: 22590863
• 负责人: SHIMIZU Eiji
• 金额: $ 2.75万
• 依托单位: Tottori University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22590863/
• 关键词: 胸膜中皮腫; 分子標的治療

Most patients with malignant pleural mesothelioma (MPM) have a history of exposure to carcinogenic asbestos fibers, and the latent period of this disease is more than 40 years. Therefore, the numbers of the patients are now still increasing. Cetuximab is a chimeric mouse-human antibody directed against the extracellular domain of EGFRand has been shown remarkable effects for colorectal cancer and head and neck cancer. However, no published in vitro or in vivo studies have focused on the effect of cetuximab against MPM. In the present study, we found that cetuximab has potent anti-tumor activity against MPM in combination with the methods to enhance its immunological function, antibody-dependent cellular cytotoxicity (ADCC) activity. Our data indicate the important role of ADCC activity in the mechanism of action of cetuximab and underscore the promising potential of cetuximab as a new class of therapeutic agent for use against MPM.

恶性胸膜间皮瘤（malignant pleural mesothelioma， MPM）患者多有接触致癌石棉纤维的历史，本病潜伏期在40年以上。因此，患者的数量目前仍在增加。西妥昔单抗是一种针对EGFRand细胞外结构域的小鼠-人嵌合抗体，已被证明对结直肠癌和头颈癌有显著的疗效。然而，没有发表的体外或体内研究集中在西妥昔单抗对MPM的影响上。在本研究中，我们发现西妥昔单抗与增强其免疫功能和抗体依赖性细胞毒性（ADCC）活性的方法相结合，对MPM具有较强的抗肿瘤活性。我们的数据表明了ADCC活性在西妥昔单抗作用机制中的重要作用，并强调了西妥昔单抗作为一种新型治疗MPM的药物的潜力。

项目成果

Circulating serum ULBP2 in patients with various lung diseases

各种肺部疾病患者循环血清ULBP2

• 发表时间: 2012
• 作者: Kinoshita N;Chikumi H;Yamaguchi K;Takata M;Nakamoto M;Kodani M;Matsumoto S;Kawasaki Y;Tadashi I;Shimizu E
• 通讯作者: Shimizu E

Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients

• DOI: 10.1111/j.1349-7006.2012.02330.x
• 发表时间: 2012-08-01
• 期刊: CANCER SCIENCE
• 影响因子: 5.7
• 作者: Yamaguchi, Kosuke;Chikumi, Hiroki;Shimizu, Eiji
• 通讯作者: Shimizu, Eiji

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity

• DOI: 10.4161/cbt.19238
• 发表时间: 2012-04-01
• 期刊: CANCER BIOLOGY & THERAPY
• 影响因子: 3.6
• 作者: Takata, Miyako;Chikumi, Hiroki;Shimizu, Eiji
• 通讯作者: Shimizu, Eiji